28.05.2025 09:15:00
|
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more manageable tariff levels has grown. Trump struck a deal with the U.K. and has signed an initial agreement with China, signs that the impact of tariffs may be limited.And this has helped the S&P 500, (SNPINDEX: ^GSPC), the Nasdaq Composite (NASDAQINDEX: ^IXIC), and the Dow Jones Industrial Average (DJINDICES: ^DJI) rebound from lows. At the same time, many members of these indexes still are trading at reasonable levels, making now a great time to go bargain hunting. In fact, one stock actually bucked the trend of the market, climbing through the worst of the tariff turmoil, but in recent weeks has tumbled, offering us an opportunity to buy on the dip.This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF) treatment market. The company has slipped 14% in May, though, after an earnings disappointment -- an illegal generic CF drug in Russia hurt sales in the latest quarter. This is not an issue that will disrupt long-term growth, though, so let's check out three reasons why you should buy shares of Vertex like there's no tomorrow.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
03.06.25 |
NASDAQ Composite Index-Titel Vertex Pharmaceuticals-Aktie: So viel hätten Anleger an einem Vertex Pharmaceuticals-Investment von vor einem Jahr verloren (finanzen.at) | |
27.05.25 |
NASDAQ Composite Index-Titel Vertex Pharmaceuticals-Aktie: So viel Gewinn hätte ein Investment in Vertex Pharmaceuticals von vor 10 Jahren eingefahren (finanzen.at) | |
20.05.25 |
NASDAQ Composite Index-Wert Vertex Pharmaceuticals-Aktie: So viel hätten Anleger an einem Vertex Pharmaceuticals-Investment von vor 5 Jahren verdient (finanzen.at) | |
20.05.25 |
Börse New York: NASDAQ 100 fällt zum Start (finanzen.at) | |
15.05.25 |
Börse New York in Grün: Schlussendlich Gewinne im NASDAQ 100 (finanzen.at) | |
15.05.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 in der Gewinnzone (finanzen.at) | |
15.05.25 |
Pluszeichen in New York: Anleger lassen NASDAQ 100 mittags steigen (finanzen.at) | |
14.05.25 |
Mittwochshandel in New York: NASDAQ 100 verbucht Gewinne (finanzen.at) |